HomeCompareBMNDF vs PLD

BMNDF vs PLD: Dividend Comparison 2026

BMNDF yields 18181.82% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BMNDF wins by $658828.95M in total portfolio value
10 years
BMNDF
BMNDF
● Live price
18181.82%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$658834.86M
Annual income
$54,543,841,013.90
Full BMNDF calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — BMNDF vs PLD

📍 BMNDF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBMNDFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BMNDF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BMNDF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BMNDF
Annual income on $10K today (after 15% tax)
$1,545,454.55/yr
After 10yr DRIP, annual income (after tax)
$46,362,264,861.82/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, BMNDF beats the other by $46,358,226,745.40/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BMNDF + PLD for your $10,000?

BMNDF: 50%PLD: 50%
100% PLD50/50100% BMNDF
Portfolio after 10yr
$329420.38M
Annual income
$27,274,295,869.54/yr
Blended yield
8.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

BMNDF
No analyst data
Altman Z
-414.3
Piotroski
1/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BMNDF buys
0
PLD buys
0
No recent congressional trades found for BMNDF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBMNDFPLD
Forward yield18181.82%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%74.4%
Portfolio after 10y$658834.86M$5.91M
Annual income after 10y$54,543,841,013.90$4,750,725.19
Total dividends collected$553757.55M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: BMNDF vs PLD ($10,000, DRIP)

YearBMNDF PortfolioBMNDF Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$919,791$909,090.91$11,241$540.96+$908.5KBMNDF
2$40,057,707$39,073,530.55$13,019$991.13+$40.04MBMNDF
3$838,042,485$795,180,738.70$15,801$1,870.97+$838.03MBMNDF
4$8,670,481,609$7,773,776,150.53$20,609$3,701.21+$8670.46MBMNDF
5$46,860,761,379$37,583,346,056.88$29,919$7,867.97+$46860.73MBMNDF
6$145,058,842,015$94,917,827,338.98$50,631$18,617.74+$145058.79MBMNDF
7$292,512,437,337$137,299,476,380.97$105,528$51,352.20+$292512.33MBMNDF
8$442,364,760,258$129,376,452,307.77$287,364$174,449.42+$442364.47MBMNDF
9$564,757,963,223$91,427,669,747.44$1,081,760$774,280.77+$564756.88MBMNDF
10$658,834,861,663$54,543,841,013.90$5,908,209$4,750,725.19+$658828.95MBMNDF

BMNDF vs PLD: Complete Analysis 2026

BMNDFStock

Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; and BMND08, a 5-Methoxy-N,N-dimethyltryptamine based candidate that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer's-type cognitive impairment. It is also developing new and preclinical drug candidates, including BMND02 for treating fibromyalgia, BMND03 for treating addictive disorders, BMND05 for treating chronic pain, BMND06 for treating inflammation, and BMND07 for treating major depressive disorder. The company is headquartered in Canelones, Uruguay.

Full BMNDF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this BMNDF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BMNDF vs SCHDBMNDF vs JEPIBMNDF vs OBMNDF vs KOBMNDF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.